AbstractBySubCategory

Cytotoxic Chemotherapy

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

2015 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. Edith A. Perez

1001

Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). Marco Colleoni

1002

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. Sarah Schellhorn Mougalian

1009

Absence of disease-specific survival improvement over time among breast cancer patients age 70 and older: 1990-2007. Henry G. Kaplan

1010

Role of β blocker and angiotensin antagonist for the prophylaxis of early onset anthracycline-induced ventricular dysfunction: A meta-analysis of five randomized controlled trials. Nicole Vincelette

1021

Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. Hyman B. Muss

1022

Association of disregulated neuronal and peripheral BDNF with vulnerability to paclitaxel-induced peripheral neuropathy. David Azoulay

1023

Hippocampal memory impairment in breast cancer survivors after chemotherapy measurement using covert testing. Anthony J. Ryals

1024

Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II α, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer. Yen-Shen Lu

1025

The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY). Tetsuhiro Yoshinami

1026

Utilization of neoadjuvant systemic therapy (NST) for breast cancer. Jahan J. Mohiuddin

1027

A comparison of toxicity profiles between standard and lower dose capecitabine (CAP) in breast cancer (BC): a meta-analysis. Tomohiro Funakoshi

1028

Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An Oncosur Study Group study. Eva Ciruelos

1029

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid. Javier Cortes

1031

Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. Oleg Gluz

1032

Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). Ravi Ramjeesingh

1033

A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. Jose Vila

1034

Direct effects on bone metabolism induced by perioperative anthracycline- and/or taxane-based chemotherapy depend on the menopausal status of patients with primary breast cancer. Nadine Rauschenbach

1035

Death during study treatment: An evaluation of events in 31 German clinical trials. Jenny Furlanetto

1036

Tumor infiltrating lymphocytes (TILs) in HER2 positive breast cancer: Evaluation according to the new recommendations by the international TILs working group 2014. Houman Nafisi

1037

A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I. Hiroyuki Yasojima

1038

Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression. Qamar J. Khan

1039

Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC). Tarek M. A. Abdel-Fatah

1040

A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). Manish Sharma

1041

Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy. Alejandro Martinez-Bueno

1042

A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends. Jacques Raphael

1043

Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer. Theodoros Foukakis

1044

Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target. Todd A. Hembrough

1045

Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999-2012. Diogo Bugano Diniz Gomes

1046

Pre-treatment Near-Infrared Spectral Tomography (NIRST) to predict pathologic complete response to neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (LABC). Peter Kaufman

1047

Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC). Nicholas Martin LeCroy

1048

Clinical evaluation of germline polymorphisms (SNPs) associated with capecitabine (C) toxicity (tox) in metastatic breast cancer (MBC). Peter H. O'Donnell

1049

The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis. Rodrigo Ramella Munhoz

1050

FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. Christopher Riedl

1051

The PerSeUS-BC01 study: A phase II study of nab-PTX followed by EC as neoadjuvant chemotherapy in breast cancer patients. Manabu Futamura

e12000

Comparison of neoadjuvant chemotherapy (NACT) with 5-flurouracil, epirubicin (100mg), cyclophosphamide (FEC100) followed by docetaxel (D) (75mg) versus adriamycin and cyclophosphamide (AC) followed by docetaxel (100mg) in locally advanced breast cancer (LABC): A randomized clinical study. Smita Kayal

e12002

Tumour volume analysis (TVA) as applied to a pilot randomized study of neoadjuvant endocrine versus neoadjuvant chemotherapy (NEOCENT). Angus Gordon

e12003

Is response classification with PERCIST in stage IV breast cancer influenced by the number of lesions assessed? Katja Pinker

e12004

Antiemesis prophylaxis among breast cancer (BC) patients receiving highly emetogenic chemotherapy. Mariana Chavez-Mac Gregor

e12005

Clinical observation of external compound Chinese herbal extract LC09 with capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Yanni Lou

e12006

MiR-141 to confer the docetaxel chemoresistance of breast cancer cells via regulating EIF4E expression. Lu Yue

e12007

Utilization of neoadjuvant therapy and rates of pathologic complete response at Commission on Cancer accredited centers across the United States. Olga Kantor

e12010

Predictive value of the pattern of β-catenin expression for pathological response to neoadjuvant chemotherapy in breast cancer patients. Shereef Elsamany

e12013

Combination of liposomal doxorubicine plus gemcitabine in heavily pretreated metastatic breast cancer patients: A single center experience. Juan Pablo Fusco

e12015

TrichostatinA to stimulate expression of Bridge-1 and Smad2, 3 and 4 of the ActivinA signaling cascade: Bridge-1-siRNA to enhance antiproliferative response to ActivinA in human breast cancer cells MCF-7. Constanze Banz-Jansen

e12016

A phase II, multicenter, single-arm study of eribulin mesilate as first-line therapy for HER2-negative locally advanced or metastatic breast cancer. Seika Tei

e12017

The application of antibotoxsome, a novel cytotoxic conjugate, in cell death in in vitro models of pancreatic, liver, breast, cervical cancer, and myeloma. Simon Tazzyman

e12018

The feasibility and tolerability of newer chemotherapy regimens in the adjuvant setting in older patients with breast cancer. Rahul Ladwa

e12019

Recombinant hybrid protein of tumor necrosis factor in neoadjuvant treatment of patients with locally advanced breast cancer. Natalia Podzorova

e12020

Safety and efficacy of scalp hypothermia to prevent chemotherapy-induced alopecia: A study of a scalp-cooling system used in breast cancer women in a Mexican public hospital. Saul Campos Gomez

e12021

Clinical profile and prognosis of metastatic breast cancer (MBC) patients with long-lasting response to eribulin (E): Results of the EXTER study. Francisco Ayala

e12022

Multi-istitutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial). Vincenzo Adamo

e12023

Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer. Maria Cristina Aguilar Martinez

e12024

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). Mustafa Khasraw

e12025

Neoadjuvant chemotherapy (NC) in invasive breast cancer (IBC) subtypes: Outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT). Antonella Ferro

e12027

Could tumor growth rate provide useful information to predict the efficacy of eribulin? Eleonora De Maio

e12028

Community platinum use in neoadjuvant or adjuvant HER2- breast cancer. Laura Rose Bobolts

e12029

The role of c-peptide in chemotherapy induced peripheral neuropathy (CIPN) during taxans treatment of early breast cancer patients. Agnieszka Irena Jagiello-Gruszfeld

e12030

Safety of eribulin in Korean patients with metastatic breast cancer. Yeon Hee Park

e12031

From preclinical to phase II: Using virtual tumor clinical model to predict the efficacy of randomised phase II trials. Eric Fernandez

e12032

Pathological response and surgical outcome with neoadjuvant chemotherapy (NACT) in Saudi Arabian breast cancer (BC) patients. Hossam A. Abdelrahman

e12033

Concurrent capecitabine and radiotherapy for high risk breast cancer. Uma Goyal

e12034

Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer. Kadri Altundag

e12035

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. Ozturk Ates

e12036

Neuroendocrine breast cancer: A single center experience. Vildan Tasdemir

e12037

Do responses in PET/CT correlate with pathological complete response after neoadjuvant chemotherapy in locally advanced breast cancer? Serap Kaya

e12038

Inflammatory breast cancer in Morocco: Biological features and outcome. Zineb Benbrahim El Mekkeoui

e12039

Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial. Icro Meattini

TPS1100

A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). Andreas Schneeweiss

TPS1101

Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC). Shannon Puhalla

TPS1102